Introduction
============

Adaptogens were initially defined as substances that enhance the "state of non-specific resistance" in stress (Brekhman and Dardymov, [@B12]; Panossian, [@B49]), a physiological condition that is linked with various disorders of the neuroendocrine--immune system (Stratakis and Chrousos, [@B69]). This definition has been updated as "*a new class of metabolic regulators which increase the ability of an organism to adapt to environmental factors and to avoid damage from such factors*" (Panossian et al., [@B58]). The term adaptogen was used as a functional claim for certain botanicals and herbal medicinal products in Europe and the USA and the adaptogen concept is now a generally accepted concept (Samuelsson and Bohlin, [@B62]). A number of clinical trials clearly demonstrated that adaptogens exert an anti-fatigue effect that increases mental work capacity against a background of stress and fatigue, particularly in tolerance to mental exhaustion and enhanced attention (Panossian and Wikman, [@B54]). Studies on animals and isolated cells have revealed that adaptogens exhibit neuroprotective, anti-fatigue, antidepressive, anxiolytic, nootropic, and CNS stimulating and tonic effects (Panossian and Wagner, [@B51]; Panossian and Wikman, [@B54]). In contrast to conventional stimulants such as sympathomimetics (e.g., ephedrine, fenfluramine, phentermine, prolintane) and general tonics, adaptogens do not possess addiction, tolerance and abuse potentials, or impair mental function, or lead to psychotic symptoms with long term use (Panossian and Wikman, [@B54]). Recent pharmacological studies of a number of adaptogens have provided a rationale for these effects also at the molecular level (Panossian and Wikman, [@B54]). The stress--protective activity of adaptogens is associated with regulation of homeostasis *via* several mechanisms of action which are linked to the hypothalamic--pituitary--adrenal (HPA) axis and the regulation of key mediators of the stress response, including cortisol, nitric oxide, stress-activated protein kinase c-Jun N-terminal protein kinase (JNK; Panossian et al., [@B50]), forkhead box O (FoxO) transcription factor (DAF-16; Wiegant et al., [@B74]), and molecular chaperones (Chiu and Ko, [@B16]; Panossian and Wikman, [@B54]). However, it still remains unclear what the primary upstream targets are in response to stimulation by adaptogens. In this study, we investigate whether heat shock factor 1 (HSF1) and Neuropeptide Y (NPY) might be one of the primary upstream targets of adaptogens in neuroglia cells.

Neuropeptide Y is a stress--responsive hormone widely distributed in the central and peripheral nervous system (Tatemoto et al., [@B70]; Irwin, [@B29]). In the brain the concentrations of NPY are significantly higher than other neuropeptides, and is found mainly in the limbic system, including the amygdala and the hypothalamus, which are areas of the brain involved in the regulation of emotional behaviors and stress response (Dumont et al., [@B22]; Smialowska et al., [@B67]). In the peripheral nervous system, NPY is concentrated in sympathetic nerve endings (Irwin, [@B29]). Sympathoadrenal activation during the stress response results in NPY release from the sympathetic nerve endings either alone or with catecholamines (Morris et al., [@B44]). NPY release follows stressors including strenuous exercise (Karamouzis et al., [@B30]), panic disorders (Boulenger et al., [@B11]), cold exposure (Kellogg, [@B31]), and chronic fatigue syndrome (CFS; Fletcher et al., [@B24]). The elevation of NPY in blood of CFS patients is associated with severity of stress, negative mood, and clinical symptoms (Fletcher et al., [@B24]). On the other hand, psychological stress elevated plasma NPY in healthy subjects (Morgan et al., [@B42]). In the periphery, sympathetic nerve- and platelet-derived NPY act in a stimulatory fashion; synergizing with glucocorticoids and catecholamines to potentiate the stress response, induce vasoconstriction and increase vascular smooth muscle cell proliferation. However, in the brain NPY acts as an anxiolytic and inhibits sympathetic activity which results in lowering blood pressure and heart rate (Morris et al., [@B44]; Kuo et al., [@B34]), and inhibiting the production of cortisol in human adrenal cells (Kempna et al., [@B32]). NPY can regulate both immune cells and neuronal cells, e.g., NPY strongly inhibits NO synthesis through Y(1) receptor activation, which prevents IL-1β release and thus inhibits nuclear translocation of NF-κB in microglia (Ferreira et al., [@B23]). NPY plays a protective role in viral infections associated with glial cell activation and the production of pro-inflammatory cytokines in the CNS (Du et al., [@B21]). It has been suggested that the stimulation of NPY gene expression is related to food deprivation and its overexpression causes disordered energy balance leading to increased eating (Yang et al., [@B77]). Within cells, NPY decreases the expression of mitochondrial uncoupling protein, thereby promoting ATP formation (Billington et al., [@B9]). NPY stimulates the corticotrophic axis (Small et al., [@B66]), modulates the secretion of various hypothalamic neuropeptides and cognition (Redrobe et al., [@B61]). Administration of NPY reduced cortisol secretion during night hours in healthy subjects (Antonijevic et al., [@B2]). In addition, NPY is known to play a role in the pathophysiology of depression (Heilig et al., [@B27]). It has been shown that NPY displayed antidepressant-like activity in the rat forced swimming test (Stogner and Holmes, [@B68]; Redrobe et al., [@B60]). Human studies have revealed a role for NPY in adaptation to stress ("buffering" the harmful effects of stress; Morgan et al., [@B43], [@B42]; Morales-Medina et al., [@B41]). There is a plethora of pre-clinical and clinical evidence suggesting a mood and cognitive performance improving action for NPY (Morgan et al., [@B43]; Fletcher et al., [@B24]). Higher levels of NPY have been observed in soldiers who either present with reduced psychological distress or belong to the elite Special Forces branch (Morgan et al., [@B43], [@B42]). In contrast, decreased levels of NPY were observed in depression and in brain tissues of suicide victims (Morales-Medina et al., [@B41]).

The 72 kDa heat shock protein (Hsp72) plays an important role in pharmacological effects of adaptogens (Panossian et al., [@B56]). Hsp72 functions both as a chaperone by binding important antigenic peptides for delivery to antigen presenting cells (APC), and as a cytokine by stimulating pro-inflammatory cytokine release. This dual function of Hsp72 is termed the chaperokine activity (Asea, [@B5], [@B3], [@B4], [@B6]; Hecker and McGarvey, [@B26]). Recently, we demonstrated the stimulating effect of ADAPT-232, a fixed combination of extracts of three most efficient adaptogens (*Rhodiola rosea, Eleutherococcus senticosus*, and *Schisandra chinensis*), is associated with significant increase of circulated Hsp72 in rats (Panossian et al., [@B55]). However, the target cells for ADAPT-232-induced effects or the cells releasing Hsp72 have not yet been identified.

Materials and Methods {#s1}
=====================

Test article
------------

ADAPT-232 forte is a proprietary name of a fixed combination of three genuine (native) extracts of *E. senticosus* (Rupr. et Maxim) Harms root, *S. chinensis* (Turcz.) Baill. root, *R. rosea* L., root, characterized for the content of eleutherosides E and B (0.17%), schisandrin and γ-schisandrin (0.85%), salidroside (0.33%), tyrosol (0.07%), rosavin (0.37%), triandrin (0.01%; Panossian et al., [@B55]). The amounts of the active markers salidroside, rosavin, tyrosol, triandrin, eleutheroside B, eleutheroside E, schizandrin, and γ-schizandrin were determined by analytical RP-HPLC using an acetonitrile--water gradient system as mobile phase. Peaks were detected by UV-PAD and analytes quantified at 221 nm (rhodioloside and tyrosol), 252 nm (rosavin), 262 nm (triandrin), 220 nm (eleutheroside B), 210 nm (eleutheroside E, schizandrin, and γ-schizandrin). Analytical methods were validated for selectivity, peak purity, precision (RSD \< 5%), and accuracy in the range 50--150% of the target amounts of analytes in the tablets in accordance with ICH guidelines using Effi Validation 3 software (version 1.03) for testing and calibration laboratories subject to EN ISO/IEC 17 025:2001. Samples used in experiments were prepared by dilution of stock solutions of ADAPT-232 (10 mg/ml) or salidroside (3 mg/ml, 10^−2^ M) with PBS. Fifty microliters of working solutions were added to 10 ml of cell culture in order to obtain final concentrations of 0.5, 1, 5, and 10 μM salidroside and 0.005, 0.05, 0.5, and 5 μg/ml of ADAPT-232 (containing 0.05, 0.5, 5, and 50 nM salidroside) in culture media.

Reagents
--------

Control peptide, PB1 is a synthetic peptide containing an N-terminal cysteine (CTRSRHSSYPNEYEEDEEMEEEL); the sequence is derived from mouse Bad (New England Biolabs, Ipswich, MA, USA). The NPY peptide (Sequence H-Tyr-Pro-Ser-Lys-Pro-Asp-Asn-Pro-Gly-Glu-Asp-Ala-Pro-Ala-Glu-Asp-Met-Ala-Arg-Tyr-Tyr-Ser-Ala-Leu-Arg-His-Tyr-Ile-Asn-Leu-Ile-Thr-Arg-Gln-Arg-Tyr-NH~2~ acetate salt) was purchased from Bachem (Torrance, CA, USA). NPY-siRNA and HSF1-siRNA were purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Hsp72-siRNA and control-siRNA were purchased from Dharmacon RNA Technologies (Lafayette, CO, USA).

Cell lines and culture conditions
---------------------------------

The human neuroglia cell line T98G (ATCC, CRL-1690) has a hyperpentaploid chromosome count that was derived from a 61-year-old Caucasian male with glioblastoma multiforme. Human neuroglia T98G cells were cultured from ATCC-formulated Eagle's Minimum Essential Medium (Catalog No. 30-2003) with fetal bovine serum to a final concentration of 10%, 100 U/ml penicillin, 100 μg/ml streptomycin (ICN, Aurora, OH, USA). To avoid stress induced by cell overgrowth, cultures were maintained in a 37°C incubator in humidified air with 5% CO~2~ atmosphere. Cells were maintained at a density of 2 × 10^5^ cells/ml and passaged with fresh complete medium every 3--4 days. Cell viability was assessed using trypan blue exclusion test and routinely found to contain \<5% dead cells.

Protein separation and western blot analysis
--------------------------------------------

Following various treatment protocols cells were washed once with complete medium, centrifuged, and pellets lysed with 100 μl of lysing buffer containing a cocktail of protease inhibitors (antipain, bestain, chymostatin, E-64, pepstatin, phosphoramidon, pefabloc, EDTA, aprotinin; Complete Protease Inhibitor Cocktail Tablets^®^, Roche Diagnostics). Cells were then incubated for 30 min on ice and sonicated (Brandson 1510) for 15 min. The cell suspension was passed through a 26-gage needle and protein quantification was performed using the Bradford method. Proteins were separated in a precast 10% SDS-PAGE Novex^®^ Tricine gel (Invitrogen) by carefully placing 3 μg of protein in each lane. Nitrocellulose membrane (GIBCO BRL) was used to transfer the proteins and the membrane blocked with 5% skim milk (in TBS 1% pH 7.4 and 0.01% Tween-20) and incubated for 1 h at room temperature with appropriate primary antibody; anti-Hsp72 (Stressgen Biotechnologies, BC, Canada), anti-NPY (Assay Design, BC, Canada), or anti-β-actin (Oncogene, San Diego, CA, USA). Blots were incubated 50 min at room temperature with 0.5 μg of appropriate species matched anti-peroxidase and the reaction was detected using the Luminol reagent for chemiluminescence (Santa Cruz Biotechnology). The intensity of the bands were analyzed by densitometry with a video densitometer (Chemilmager™ 5500; Alpha Innotech, San Leandro, CA, USA) using the AAB software (American Applied Biology).

Measurement of lactate dehydrogenase release
--------------------------------------------

Lactate dehydrogenase (LDH) is a stable cytosolic enzyme that is released upon cell lysis. LDH released into cell culture media by dead cells and total LDH contained in living cells was measured using the CytoTox 96 Non-Radioactive Cytotoxicity Assay according to the manufacturer's instructions (Promega, Madison, WI, USA). Briefly, after various treatment protocols, culture medium (500 μl) was removed and the remaining cells lysed by adding 500 μl of 5% Triton X-100 solution. After 30 min at room temperature, cell lysate was recovered and incubated for an additional 30 min in the dark with a buffer containing NAD^+^, lactate, and tetrazolium. LDH converts lactate to pyruvate, generating NADH which reduces tetrazolium (yellow) to formazan (red), which is detected by fluorescence (490 nm). LDH release, a marker for cell death was expressed as a percentage of the LDH in the medium over the total LDH (lysate).

Enzyme linked immunossorbant assay
----------------------------------

After treatment the human neuroglia cell line T98G was centrifuged to discard floating cells and cellular debris and the total protein content was determined by Bradford analysis using bovine serum albumin as a standard. The supernatant was aliquoted and treated with or without 1% Triton X-100 or 1% Lubrol WX or 0.5% Brij 98 for 10 min at 4°C with gentle rocking and Hsp72 content measured by standard sandwich Enzyme linked immunossorbant assay (ELISA). Briefly, 96-well microtiter plates (Nunc Immunoplate Maxisorp; Life Technologies) were coated with murine monoclonal anti-human Hsp72 (clone C92F3A-5; Stressgen) in carbonate buffer, pH 9.5 (2 μg/mL) overnight at 4°C. Plates were then washed with PBS containing 1% Tween-20 (PBS-T) and blocked by incubation with 1% bovine serum albumin in PBS-T. Supernatant was added and bound Hsp72 was detected by the addition of rabbit polyclonal anti-Hsp72 antibody (SPA-812; Stressgen). Bound polyclonal antibody was detected with alkaline phosphatase-conjugated murine monoclonal antibody to rabbit immunoglobulins (Sigma Chemical Co), followed by *p*-nitrophenyl phosphate substrate (Sigma Chemical Co). The resultant absorbance was measured at 405 nm with a Bio-Rad Benmark Plus plate reader. Standard dose--response curves were generated in parallel with Hsp72 (0--20,000 ng/mL; Stressgen), and the concentrations of Hsp72 were determined by reference to these standard curves with ASSAYZAP data analysis software (BIOSOFT). The interassay variability of the Hsp72 immunoassays was \<10%.

NPY enzyme immunoassay
----------------------

Human neuroglia cells were grown to 75% confluence. Twenty-four hours prior to measuring NPY release, cell culture medium was replaced with serum-free DMEM, then incubated with ADAPT-232, or salidroside, or exposed to heat shock (41°C, 60 min) and incubated for 24 h in a 37°C incubator. Supernatant was recovered in quadruplicates, centrifuged to clear cellular debris and NPY concentration was measured using the NPY enzyme immunoassay kit (assay sensitivity of 0.09 ng/ml) according to the manufacturer's instructions (Phoenix Pharmaceuticals, CA, USA). Briefly, cleared supernatant was added to 96-well plates containing primary antibody and biotinylated peptide and incubated at room temperature for 2 h. Plates were washed and SA--HRP solution was added to the well and incubated for a further 1 h at room temperature. After washing the plates TMB substrate was added and incubated for an additional 1 h at room temperature. The test was terminated by adding 2 N HCl to the wells. The resultant absorbance was measured at 450 nm with a Bio-Rad Benmark Plus plate reader. The concentration of NPY was determined by reference to these standard curves with ASSAYZAP data analysis software (BIOSOFT). The interassay variability of the NPY enzyme immunoassays was \<10%.

siRNA-mediated gene silencing assays
------------------------------------

The hsp72 gene silencing was achieved by using a vector-based system to produce hairpin RNA. The criteria that were used to silence the *hsp72* gene have previously been established. To design the siRNA duplexes a search for 23-nucleotide motif with AA (N19) TT was performed in which the target sites were selected from a gene sequence beginning at 50--100 nucleotides downstream of the start codon. Hits with ∼50% G/C-content were selected and anti-sense RNA was synthesized as the complement to position 1--21 of the 23-nucleotide motif. Finally, symmetric 3′-overhangs that help to ensure that siRNA are formed with approximately equal ratios of sense and anti-sense target RNA-cleaving siRNA. The 21-base pair product, Hsp72-siRNA was cloned into the pSuper vector under the restriction of *Bgl*II and *Hin*dIII. This construct was then co-transfected with a green fluorescent protein (GFP) plasmid into the THP1 human monocytic cells. Splicing of the hairpin resulted in 21-mer long dsRNA. Psuper vector (Oligoengine, Seattle, WA, USA) was used to introduce a 64-base oligomer to form the hairpin with Hsp72 specific sequence. A chemically synthesized 21-mer-nucleotide DNA to silence the *hsp72* gene was used and cloned into the pSuper vector-based silencing (Oligoengine). The primers were designed using web-based proprietary software from Oligoengine and three 21-mer gene sequences were selected that predicted it would successfully silence the *hsp72* gene. The sequence used in this study was Hsp72 sequence 5′-AGCCCGAGCTGGGAACCATT-3′ (GenBank Accession Number LO7577). This 21-base was synthesized with defined sequences to provide two restriction sites (*Bgl*II and *Hin*dIII) and on transcription form a hairpin, in order to initiate gene silencing. The total length of the primer was 64-mer including the specific sequences of Hsp72. A complementary oligonucleotide was also synthesized from Oligoengine (Seattle, WA, USA). The primers were incubated in annealing buffer (100 mM potassium acetate, 30 mM HEPES--KOH pH 7.4, 2 mM magnesium acetate) at 95°C for 5 min and incubated overnight at room temperature. After digesting double stranded oligo and pSuper vector with *Hin*dIII and *Bgl*II restriction enzymes, primers were annealed and cloned into the pSuper vector. Positive clones were sequenced.

Transfection and cell sorting
-----------------------------

THP1 cells were transfected with pSuper-Hsp72 and pGFP using the lipid transfection reagent, Effectene, according to the manufacturer's instructions (Qiagen, Valencia, CA, USA). Briefly, 3 × 10^5^ exponentially growing cells were seeded in 60 mm tissue culture plates and a mixture of 1 μg GFP plasmid DNA and 1 μg pSuper-Hsp72 plasmid in Effectene was added to the cells and incubated for 18 h at 37°C. After 48 h cells were harvested and immediately sorted into GFP positive and negative subpopulations using a MoFlow cytometer (Dakocytomation, Carpinteria, CA, USA). Briefly, individual cells were gated on the basis of forward scatter (FSC) and orthogonal scatter (SSC). The photomultiplier (PMT) for GFP (FL1-height) was set on a logarithmic scale. Cell debris was excluded by raising the FSC-height PMT threshold. The flow rate was adjusted to \<200 cells/s and at least 10^5^ cells were sorted for each sample group.

Statistical analysis
--------------------

Data obtained from Western blot was analyzed according to the relationship between the signal intensity and the area and presented as optical density (OD). Data from flow cytometry was shown as histograms and fluorescent arbitrary units and the mean fluorescent intensity was obtained to compare between groups. Data management and statistical analyses were performed using GraphPad (San Diego, CA, USA) and Prism software (version 3.03 for Windows). The significance of the between-group differences (at 95% confidence intervals) were determined using one-way parametric analysis of variance (ANOVA) with Tukey's multiple comparison post test. The *F* test statistic was found by dividing the between-group variance by the within group variance (mean squared deviations from the mean, MSB/MSW, obtained by dividing of the Sum of Squares on the degrees of freedom (df) for the between group and within group). Data were shown in absolute (ng/ml, μM) or normalized (as percentages) values, mean and SD, and *p* values \< 0.05 were considered statistically significant.

Results
=======

In this study, we demonstrate that neuroglia cells are one possible target cell that mediates ADAPT-232-induced effects. We further demonstrate that ADAPT-232 stimulates the expression of NPY and Hsp72 release from neuroglia cells in a concentration-dependent fashion. Our present study suggests NPY might be one of the primary upstream targets of adaptogens. Our present study suggests that HSF1 and NPY might be the primary upstream targets of adaptogens.

ADAPT-232 stimulates the expression of NPY and Hsp72 in human neuroglia cells
-----------------------------------------------------------------------------

Human neuroglia cells were treated with ADAPT-232 and the expression of Hsp72 and NPY was measured by Western blot analysis. We demonstrated that treatment of human neuroglia cells with ADAPT-232 or salidroside dose-dependently increased NPY expression and the expression the stress protein, Hsp72. Maximum effect of ADAPT-232 required 0.5 μg/ml of the genuine plant extracts containing salidroside in the final concentration of 5.5 nM (*p* \< 0.01) (Figure [1](#F1){ref-type="fig"}). Interestingly, the treatment of human neuroglia cells with salidroside induced a similar dose--response curves, albeit, requiring 1,000 times higher concentration of salidroside (5 μM) to achieve maximum NPY expression (*p* \< 0.01; Figure [2](#F2){ref-type="fig"}).

![**ADAPT-232 dose-dependently increases NPY and Hsp72 expression in human neuroglia cells**. ADAPT-232 and salidroside was admixed with 10^6^ human neuroglia cells at the indicated concentrations and incubated for 24 h at 37°C in 5% CO~2~ atmosphere. Cells were lysed and NPY Hsp72 protein expression was determined using Western blot analysis as described in detail in the Section ["Materials and Methods."](#s1){ref-type="sec"} The intensity of the bands were analyzed by densitometry with a video densitometer (Chemilmager™ 5500; Alpha Innotech, San Leandro, CA, USA) using the AAB software (American Applied Biology). Data are the percentage (%) change in protein density expression as compared to control (± SD).](fnins-06-00006-g001){#F1}

![**Salidroside dose-dependently increases NPY expression in human neuroglia cells**. Salidroside was admixed with 10^6^ human neuroglia cells at the indicated concentrations and incubated for 24 h at 37°C in 5% CO~2~ atmosphere. Cells were lysed and NPY expression was determined using Western blot analysis as described in detail in the Section ["Materials and Methods."](#s1){ref-type="sec"} The intensity of the bands were analyzed by densitometry with a video densitometer (Chemilmager™ 5500; Alpha Innotech, San Leandro, CA, USA) using the AAB software (American Applied Biology). Data are the percentage (%) change in protein density expression as compared to control (± SD).](fnins-06-00006-g002){#F2}

Human neuroglia cells release NPY and Hsp72 in response to stimulation with ADAPT-232
-------------------------------------------------------------------------------------

We previously demonstrated that ADAPT-232 strongly augments endurance of mice in a forced swimming experiment (a model that combined physical and emotional stresses), and that there was a concomitant increase in serum Hsp72 levels (Panossian et al., [@B55]). To test our working hypothesis that human neuroglia cells release Hsp72, cells were treated with ADAPT-232 or salidroside for 24 h in a 37°C incubator and the concentration of NPY and Hsp72 in the supernatant was measured by Hsp72 ELISA. We demonstrated a dose-dependent release of NPY and Hsp72 into the supernatant of cultured human neuroglia cells (*p* \< 0.0001; Table [1](#T1){ref-type="table"}). To negate the possibility that the adaptogens were inducing Hsp72 release by stimulating necrotic cell death, in the same experiment supernatant was subjected to LDH assay for the determination of cell death. We demonstrated that there was no significant increase in cell death at the concentrations of 0.005--0.5 mg/L of ADAPT-232, as compared to control (0 mg/L; PBS only) or exposure of cell to non-lethal heat shock treatment (41°C, 60 min; Table [1](#T1){ref-type="table"}).

###### 

**Human neuroglia cells release NPY and Hsp72 in response to treatment with ADAPT-232 and its active constituent salidroside**.

  Treatment (concentration)[^a^](#tfn1){ref-type="table-fn"}   Mean Hsp72 conc. (ng/ml ± SD)[^b^](#tfn2){ref-type="table-fn"}   Mean NPY conc. (ng/ml ± SD)[^c^](#tfn3){ref-type="table-fn"}   Mean cell death (% ± SD)[^d^](#tfn4){ref-type="table-fn"}   
  ------------------------------------------------------------ ---------------------------------------------------------------- -------------------------------------------------------------- ----------------------------------------------------------- ---------------
  ADAPT-232 (μg/ml)                                            Salidroside (μM)[^†^](#tfn5){ref-type="table-fn"}                                                                                                                                           
  0                                                            0                                                                35 ± 9                                                         1.2 ± 0.2                                                   8 ± 5
  0.005                                                        (0.00005)†                                                       65 ± 11                                                        3.6 ± 0.1\*                                                 9 ± 4
  0.05                                                         (0.0005)†                                                        95 ± 10\*\*                                                    5.7 ± 0.3\*\*                                               7 ± 6
  0.5                                                          (0.005)†                                                         124 ± 15\*\*                                                   9.5 ± 0.5\*\*                                               12 ± 7
  5.0                                                          (0.05)†                                                          165 ± 12\*\*                                                   9.8 ± 1.6\*\*                                               36 ± 10\*\*
                                                                                                                                *F* = 76.2                                                     *F* = 94.2                                                  *F* = 9.9
                                                                                                                                df = 19(4/15)                                                  df = 19(4/15)                                               df = 14(4/10)
                                                                                                                                *P* \< 0.0001                                                  *P* \< 0.0001                                               *P* = 0.0017
  Salidroside (μM)                                                                                                                                                                                                                                         
  0                                                                                                                             40 ± 9                                                         1.1 ± 0.3                                                   10 ± 5
  0.5                                                                                                                           57 ± 6\*                                                       6.8 ± 0.5\*\*                                               9 ± 3
  1.0                                                                                                                           145 ± 9\*\*                                                    11.9 ± 0.8\*\*                                              13 ± 4
  5.0                                                                                                                           189 ± 12\*\*                                                   21.4 ± 0.9\*\*                                              15 ± 5
  10.0                                                                                                                          209 ± 13\*\*                                                   18.9 ± 2.1\*\*                                              35 ± 11\*\*
                                                                                                                                *F* = 228.5                                                    *F* = 227.3                                                 *F* = 9.2
                                                                                                                                df = 14(4/15)                                                  df = 14(4/15)                                               df = 14(4/10)
                                                                                                                                *P* \< 0.0001                                                  *P* \< 0.0001                                               *P* = 0.0021
  Heat shock (41°C, 60 min)                                                                                                     2086 ± 276\*\*                                                 31.5 ± 10\*\*                                               23 ± 15

*†Concentration of salidroside released from ADAPT-232 in the cell culture*.

*^a^Human neuroglia cells (10^6^) were treated with various concentrations of ADAPT-232 or salidroside or exposed to heat shock (41°C, 60 min) and incubated for 24 h in a 37°C incubator*.

*^b^Twenty-four hours after treatment protocols the supernatant from human neuroglia cells were recovered, centrifuged to clear cellular debris and Hsp72 concentration was measured using the classical Hsp72 ELISA as described in detail in the Section ["Materials and Methods."](#s1){ref-type="sec"} Data are the mean concentration of Hsp72 (ng/ml ± SD) and is the sum of four independent experiments performed in quadruplicates. \**p* \< 0.05 vs control (0 μg/ml), \*\**p* \< 0.001 vs control in Tukey's multiple comparison post test*.

*^c^Human neuroglia cells were grown to 75% confluence. Twenty-four hours prior to measuring NPY release, cell culture medium was replaced with serum-free DMEM, then incubated with ADAPT-232, or salidroside, or exposed to heat shock (41°C, 60 min) and incubated for 24 h in a 37°C incubator. Supernatant was recovered in quadruplicates, centrifuged to clear cellular debris and NPY concentration was measured using the NPY enzyme immunoassay kit (assay sensitivity of 0.09 ng/ml) according to the manufacturer's instructions (Phoenix Pharmaceuticals, CA, USA). Data are the mean concentration of NPY (ng/ml ± SD) and is the sum of four independent experiments performed in quadruplicates. \**p* \< 0.05 vs control (0 μg/ml genuine extracts), *p* \< 0.001 vs control in Tukey's multiple comparison post test*.

*^d^Twenty-four hours after treatment protocols the supernatant from human neuroglia cells and viability assayed using the CytoTox 96 Non-Radioactive Cytotoxicity Assay according to the manufactures instructions (Promega), and the percentage of LDH released vs total LDH was calculated. Data are mean percentage cell death ± SD and represent three independently performed experiments in quadruplicates. \*\**p* \< 0.01 vs control (0 μg/ml genuine extracts) in Tukey's multiple comparison post test*.

ADAPT-232-induced release of Hsp72 and NPY from human neuroglia cells is dependent on the transcription factor HSF1
-------------------------------------------------------------------------------------------------------------------

We next explored the mechanistic basis for the induction of Hsp72, to determine if it was primary or secondary to the ADAPT-232 response. This is important since, if the induction of Hsp72 is a secondary event, upstream events would be of the primary interest. The treatment of human neuroglia cells with ADAPT-232 or salidroside significantly increased the expression of HSF1 as judged by Western blot analysis (Figure [3](#F3){ref-type="fig"}A). To prove that the adaptogens stimulate Hsp72 release by a mechanism dependent HSF1, the expression of HSF1 was significantly silenced using siRNA directed against *hsf-1* gene (HSF1-siRNA) before treatment with the adaptogens, as compared to neuroglia cells pre-treated with control-siRNA (Figure [3](#F3){ref-type="fig"}A). Control-siRNA is a non-targeting 20--25 nucleotide siRNA designed as a negative control, with sequences that do not target any gene product nor has any significant sequence similarity to mouse, rat, or human gene sequences, and has been tested in cell-based screens and proved to have no significant effect on cell proliferation, viability, or morphology, according to the manufacturer (Dharmacon RNA Technologies, Lafayette, CO, USA). We further demonstrated that pre-treatment of human neuroglia cells with HSF1-siRNA strongly suppressed the expression of Hsp72 (Figure [3](#F3){ref-type="fig"}B) and release of Hsp72 and NPY (Figure [5](#F5){ref-type="fig"}) stimulated by ADAPT-232 and salidroside, as compared to neuroglia cells pre-treated with control-siRNA (Figures [3](#F3){ref-type="fig"}B and [5](#F5){ref-type="fig"}A). The possibility that the release of Hsp72 from human neuroglia cells was due to cell death was negated by results showing that adaptogens increased significant release of Hsp72 as judged by ELISA (*p* \< 0.05), but there was no similar increase in cell death, as confirmed by the LDH assay.

![**Silencing HSF1 significantly suppresses ADAPT-232- and salidroside-mediated Hsp72 expression**. Human neuroglia cells (10^6^) were either pre-treated with PBS or transfected with either 10 μM control-siRNA or 10 μM HSF1-siRNA or incubated for 48 h in a 37°C incubator. Cells were then treated with either PBS or 0.5 μg/ml ADAPT or 5 μM salidroside and incubated for a further 24 h at 37°C. Cells were lysed and **(A)** HSF1 protein expression or **(B)** Hsp72 protein expression was determined using Western blot analysis as described in detail in the Section ["Materials and Methods."](#s1){ref-type="sec"} β-Actin was used as a loading control. The intensity of the bands were analyzed by densitometry with a video densitometer (Chemilmager™ 5500; Alpha Innotech) using the AAB software (American Applied Biology). Data are the percentage (%) change in specific protein density as compared to control (normalized to 100%), and are representative of three independently performed experiments with similar results.](fnins-06-00006-g003){#F3}

NPY peptide stimulates Hsp72 release from human neuroglia cells in an autocrine loop
------------------------------------------------------------------------------------

To determine if NPY peptide itself can stimulate Hsp72 expression, human neuroglia cells were treated with NPY peptide and Hsp72 release measured in the supernatant 24 h post treatment. We demonstrated that treatment of human neuroglia cells with NPY peptide dose-dependently increased the expression (Figure [4](#F4){ref-type="fig"}A) and significant release of Hsp72 (*p* \< 0.05; Figure [6](#F6){ref-type="fig"}). We further demonstrated that silencing the expression of intracellular NPY by pre-treating human neuroglia with NPY-siRNA effectively suppressed the expression of Hsp72 (Figure [4](#F4){ref-type="fig"}A). The pre-treatment of human neuroglia cells with NPY-siRNA significantly suppressed the expression of ADAPT-232- and salidroside-mediated upregulation of intracellular Hsp72 expression (Figure [4](#F4){ref-type="fig"}B) and concomitantly resulted in a significant suppression of Hsp72 release, as compared to neuroglia cells pre-treated with control-siRNA (Figure [6](#F6){ref-type="fig"}). Cell death was excluded as a possible reason for increased Hsp72 release by experiments in which culture supernatant was probed for signs of cell death using LDH assay. We demonstrated that the significant increase in Hsp72 release in response to NPY was not followed by a similar increase in cell death (Figure [6](#F6){ref-type="fig"}). To determine the role of NPY in ADAPT-232- and salidroside-mediated responses, we demonstrated that silencing NPY expression in human neuroglia cells by pre-treatment with NPY-siRNA strongly suppressed ADAPT-232- and salidroside-induced increase in Hsp72 expression, as compared to neuroglia cells pre-treated with control-siRNA (Figure [4](#F4){ref-type="fig"}C). Taken together, these findings are consistent with a recent study which reports that NPY promotes the expression of intracellular Hsp72 in rat renal vascular smooth muscle (Zhong et al., [@B78]).

![**ADAPT-232-induced expression of Hsp72 from human neuroglia cells is dependent on NPY**. Human neuroglia cells (10^6^) were either pre-treated with PBS or transfected with various concentrations of NPY-siRNA or 12 μM control-siRNA for 48 h in a 37°C incubator. Cells were then **(A)** treated with PBS or 5, 10, 15, or 20 μM NPY peptide or **(B)** treated with PBS or 0.5 μg/ml ADAPT or 5 μM salidroside or **(C)** PBS or 0.5 μg/ml ADAPT. All cells were then incubated for a further 24 h at 37°C, at which time cells were then lysed and the expression of Hsp72 protein was determined using Western blot analysis as described in detail in the Section ["Materials and Methods."](#s1){ref-type="sec"} β-Actin was used as a loading control. The intensity of the bands were analyzed by densitometry with a video densitometer (Chemilmager™ 5500; Alpha Innotech) using the AAB software (American Applied Biology). Data are the percentage (%) change in specific protein density as compared to control (normalized to 100%), and are representative of three independently performed experiments with similar results.](fnins-06-00006-g004){#F4}

Discussion
==========

ADAPT-232 is a combination of extracts of three well studied and efficient adaptogenic plants -- *R. rosea, E. senticosus*, and *S. chinensis* (Panossian and Wikman, [@B52]; Panossian et al., [@B57]). Their effects on CNS have been recently reviewed (Panossian and Wikman, [@B54]). Clinical efficacy of single and repeated doses of ADAPT-232 on cognitive functions and mental performance of healthy volunteers, cosmonauts (Bogatova et al., [@B10]; Aslanyan et al., [@B8]), and patients with pneumonia (Narimanian et al., [@B45]) have been studied. Interestingly, the long term treatment of aged rats with ADAPT-232 diminished or prevented a range of age-related disorders including malfunction of the central nervous system, loss of memory, and loss of learning ability (Makarov et al., [@B37]).

Recently, we demonstrated that ADAPT-232 significantly increased tolerance to stress, augmenting the endurance of mice in a swimming test model. This effect was associated with a dramatic increase in the blood level of circulating Hsp72 (Panossian et al., [@B55]). However, in that study the target cell was not identified. In the present study, we demonstrated that ADAPT-232 and its active constituent salidroside stimulate the expression (Figures [1](#F1){ref-type="fig"}, [2](#F2){ref-type="fig"}, [3](#F3){ref-type="fig"}B, and [4](#F4){ref-type="fig"}B,C) and release (Table [1](#T1){ref-type="table"}; Figure [5](#F5){ref-type="fig"}) of NPY and the stress protein Hsp72 from isolated human brain glioblastoma T98G cells. There is now strong evidence that NPY are synthesized in astrocytes, oligodendrocytes, microglia, and Schwann cells *in vivo* (Ubink et al., [@B72]). We speculate that human normal neuroglia cells might be one of the target cells for ADAPT-232 (and its active constituent salidroside) as well. Further studies supporting this hypothesis are currently ongoing in our laboratory (Kaur et al., in preparation).

![**ADAPT-232 and its active constituent salidroside induce the release of Hsp72 and NPY *via* a mechanism dependent on the upregulation of HSF1**. Human neuroglia cells (10^6^) were either pre-treated with PBS or transfected with either 10 μM control-siRNA (control) or 10 μM HSF1-siRNA or 12 μM NPY-siRNA or exposed to heat shock (41°C, 60 min) and incubated for 48 h in a 37°C incubator. Cells were then treated with either PBS or 0.5 μg/ml ADAPT-232 (0.005 μM salidroside) or 5 μM salidroside and incubated for a further 24 h at 37°C. Twenty-four hours after treatment protocols the supernatant from human neuroglia cells were recovered, centrifuged to clear cellular debris and (**A**) NPY or (**B**) Hsp72 concentrations were measured using the NPY enzyme immunoassay kit (assay sensitivity of 0.09 ng/ml) according to the manufacturer's instructions (Phoenix Pharmaceuticals, CA, USA), or the classical Hsp72 ELISA as described in detail in the Section ["Materials and Methods."](#s1){ref-type="sec"} Data are the mean concentration of NPY (ng/ml ± SD), Hsp72 (ng/ml ± SD), and is the sum of three independent experiments performed in quadruplicates. \**p* \< 0.05 vs control (control-siRNA). Twenty-four hours after treatment protocols the supernatant from human neuroglia cells and viability were assayed using the CytoTox 96 Non-Radioactive Cytotoxicity Assay according to the manufacturer's instructions (Promega), and the percentage of LDH released vs total LDH was calculated. Data are mean percentage cell death ± SD and represent four independently performed experiments in quadruplicates. \**p* \< 0.001 vs control (0 μg/ml genuine extracts).](fnins-06-00006-g005){#F5}

Neuropeptide Y is known to perform a wide range of biological functions through the interaction with distinct G-protein-coupled receptors (Wahlestedt and Reis, [@B73]). Table [2](#T2){ref-type="table"} illustrates the similarities in pharmacological profiles of NPY and adaptogens. Table [3](#T3){ref-type="table"} exemplifies several NPY-mediated beneficial effects and other potential effects of adaptogens in various disorders. Taken together, the data presented in Tables [2](#T2){ref-type="table"} and [3](#T3){ref-type="table"} suggests that a stress--protective activity of adaptogens is mainly associated with effects of Hsp72, while stimulating activity of adaptogens -- with NPY.

###### 

**Similarities in pharmacological profiles of adaptogens and NPY**.

  Activity                                                     NPY   Adaptogens
  ------------------------------------------------------------ ----- ------------
  Stress response modifying (protective and mimetic) effect    \+    \+
  Stimulation of HPA axis, modulation of cortisol release      \+    \+
  Stimulation of CNS system                                    \+    \+
  Effect on endocrine system (*via* cortisol, insulin, etc.)   \+    \+
  Stimulation of immune system (*via* Hsp72)                   \+    \+
  Effect on sympathetic and parasympathetic system             \+    \+
  Effect on energy homeostasis                                 \+    \+
  Anabolic effect                                              \+    \+
  Effect on physical endurance, locomotor activity             \+    \+
  Effect on cognitive function (attention, memory)             \+    \+
  Cardiovascular effects, vasoconstrictor                      \+    \+
  Anti-narcotic effect                                         \+    \+
  Cytoprotection (*via* Hsp72)                                 \+    \+
  Anti-aging (*via* Hsp72 and FoxO)                            \+    \+

*+, See the references on relevant publications, reference list and the reviews on adaptogens (Brekhman and Dardymov, [@B12]; Panossian, [@B49]; Panossian and Wagner, [@B51]; Panossian and Wikman, [@B52], [@B53], [@B54])*.

###### 

**NPY-mediated beneficial effects^‡^ and potential effects^§^ of adaptogens in various disorders**.

  Disorder/syndrome                Effect                   Adaptogens reference                                                                                                                      NPY reference
  -------------------------------- ------------------------ ----------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------
  Depression                       Antidepressive,^‡^       Darbinyan et al. ([@B19]), Panossian et al. ([@B55])                                                                                      Stogner and Holmes ([@B68]), Redrobe et al. ([@B60]), Morales-Medina et al. ([@B41], [@B40])
  Anxiety                          Anxiolytic^‡^            Bystritsky et al. ([@B13])                                                                                                                Boulenger et al. ([@B11]), Trent and Menard ([@B71]). Morales-Medina et al. ([@B40])
  Stress induced fatigue           Anti-fatigue^‡^          Brekhman and Dardymov ([@B12]), Olsson et al. ([@B47]), Panossian and Wikman ([@B53])                                                     Morgan et al. ([@B42]), Karamouzis et al. ([@B30])
  Chronic fatigue syndrome         Relief of symptoms^§^    Panossian and Wikman ([@B53])                                                                                                             Morgan et al. ([@B43]), Fletcher et al. ([@B24])
  Post-traumatic stress syndrome   Relief of symptoms^§^    --                                                                                                                                        Rasmusson et al. ([@B59])
  Metabolic syndrome               Relief of symptoms^§^    --                                                                                                                                        Abe et al. ([@B1]), Rasmusson et al. ([@B59])
  Fibromyalgia                     Relief of symptoms^§^    --                                                                                                                                        Crofford et al. ([@B18]), Di Franco et al. ([@B20]), Sedlackova et al. ([@B64])
  Anorexia nervosa                 Gain of body weight^‡^   --                                                                                                                                        Nergardh et al. ([@B46]), Himmerich et al. ([@B28]), Sedlackova et al. ([@B64])
  Bulimia                          Loss of body weigh^‡^    --                                                                                                                                        Morris et al. ([@B44])
  Asthenia                         Anti-fatigue^‡^          Brekhman and Dardymov ([@B12]), Panossian and Wagner ([@B51]), Panossian and Wikman ([@B52], [@B53], [@B54]), Panossian et al. ([@B57])   --

Neuropeptide Y is known to play an essential role in the basic mechanisms of morphine tolerance and opioid dependence (Woldbye et al., [@B75]). Morphine significantly decreases NPY levels in the hypothalamus, the striatum, and the adrenal glands (Pages et al., [@B48]). Our study is in line both with reports on morphine anti-withdrawal effect of NPY (Woldbye et al., [@B75]) and recent studies in which the anti-narcotic effect of *Rhodiola* extract has been demonstrated (Mattioli et al., [@B39]). Our study is also in line with a recent finding that salidroside (but not rosavin) at doses present in the *Rhodiola* extract, dose-dependently reduced, or abolished binge eating (Cifani et al., [@B17]). The reason for this is thus far not known. However, we hypothesize that this might be associated with the stimulation of NPY, which plays an important role in regulation of energy homeostasis, the imbalance of which is associated with eating disorders anorexia and bulimia nervosa (Sedlackova et al., [@B64]). This is in agreement with a study demonstrating that NPY acts to stimulate behavior, which precedes the food intake and actually inhibits the food intake *per se* (Nergardh et al., [@B46]). In addition, the treatment with NPY increased physical activity and decreased food intake and caused a loss of body weight (Sederholm et al., [@B63]).

Based on the results of this study we hypothesize that NPY, being itself a kind of a "host adaptogen," plays a key role in modulation of adaptogenic activity of ADAPT-232 (and possibly other plant adaptogens), increasing resistance of the organism to stress.

One of the active constituents of ADAPT is salidroside, which also stimulates expression of NPY at concentrations approximately 100--1,000 times higher than in ADAPT. It might be speculated that ADAPT contains some other active compound(s) synergistically increasing the expression of NPY. Interestingly tyrosol, salidroside, and NPY contain five tyrosine residues (Labelle et al., [@B35]), and all have the same *p*-hydroxyl-methylene residue. The importance the tyrosine moieties for brain receptors binding and NPY activity has been demonstrated (Martel et al., [@B38]). We hypothesize that the *p*-hydroxyl-methylene residue of the tyrosine unit (in polypeptide chain of NPY), and *p*-hydroxyl-ethylene residue of tyrosol and salidroside (in ADAPT-232) can compete on the receptor binding site. In support of this speculation, we demonstrated that ADAPT-232 and salidroside dose-dependently stimulate the expression (Figure [1](#F1){ref-type="fig"}) and release (Table [1](#T1){ref-type="table"}) of Hsp72 in human neuroglia cells. Again, salidroside alone is active in concentrations significantly higher than it is in ADAPT-232 reviling a similar effect on release of Hsp72 from neuroglia cells (Figure [5](#F5){ref-type="fig"}). In the next series of experiments, we demonstrated that ADAPT-232 significantly activates HSF1, a protein known to initiate the synthesis of Hsp72 (Wu, [@B76]), However, ADAPT-232 is inactive in "silent" cells transfected by HSF1-siRNA which effectively inhibits baseline levels of HSF1 expression (Figure [3](#F3){ref-type="fig"}A).

Interferences RNA technology (RNAi) was also used to abrogate the expression of HSF1 (using HSF1-siRNA) in order to clarify what is upstream of NPY, HSF1, and Hsp72 activation. Figure [5](#F5){ref-type="fig"} demonstrated that ADAPT-232 and an active constituent salidroside induce the release of Hsp72 *via* a mechanism dependent on the upregulation of HSF1. Pre-treatment of human neuroglia cells HSF1-siRNA, which silences/knock down the expression of intracellular HSF1, before treatment with ADAPT-232 or salidroside, resulted in a significant suppression of Hsp72 and NPY release (Figure [5](#F5){ref-type="fig"}). We further demonstrated that pre-treatment of human neuroglia cells with NPY-siRNA, which silences/knock down the expression of intracellular NPY, before treatment with ADAPT-232 or salidroside resulted in a significant suppression of Hsp72 expression and release (Figures [3](#F3){ref-type="fig"}A, [3](#F3){ref-type="fig"}B and [5](#F5){ref-type="fig"}).In a separate set of experiments, we demonstrated that the treatment of human neuroglia cells with NPY peptide dose-dependently increases the expression and release of Hsp72 (Figure [6](#F6){ref-type="fig"}). These results are in agreement with recent findings that NPY stimulates Hsp72 in rat renal vascular smooth muscle (Zhong et al., [@B78]).

![**Effect of NPY on Hsp72 release from human neuroglia cells**. Treatment of human neuroglia cells with NPY peptide dose-dependently increased the release of Hsp72. Human neuroglia cells (10^6^) were transfected with either 12 μM control-siRNA or 12 μM NPY-siRNA for 48 h at 37°C. Cells were then treated with either various concentrations of NPY peptide or 40 μM PB1 (control peptide) and incubated for a further 24 h at 37°C. Twenty-four hours after treatment protocols the supernatant from human neuroglia cells were recovered, centrifuged to clear cellular debris, and Hsp72 concentration was measured using the classical Hsp72 ELISA as described in detail in the Section ["Materials and Methods."](#s1){ref-type="sec"} Data are the mean concentration of Hsp72 (ng/ml ± SD) and is the sum of five independent experiments performed in quadruplicate. \**p* \< 0.05 vs control-siRNA. Twenty-four hours after treatment protocols the supernatant from human neuroglia cells and viability were assayed using the CytoTox 96 Non-Radioactive Cytotoxicity Assay according to the manufacturer's instructions (Promega), and the percentage of LDH released vs total LDH was calculated. Data are mean percentage cell death ± SD and represent three independently performed experiments in quadruplicates. \**p* \< 0.001 vs PB1 (control peptide).^‡^*p* \< 0.001 vs control-siRNA.](fnins-06-00006-g006){#F6}

In this study we demonstrated that ADAPT-232-induced expression and release of Hsp72 from glioma cells was dependent of HSF1 or NPY. The general mechanism of activation and regulation of Hsp72 by HSF1 in the brain and aging is well elucidated (Asea and Brown, [@B7]; Calderwood et al., [@B14]). However, the mechanism activation of Hsp72 by NPY still remains uncertain. The expression of NPY receptors on glial cells has been demonstrated (Canto Soler et al., [@B15]; Hashimoto et al., [@B25]). Recently, the Y(1) receptor has been demonstrated to play an essential role in mediating NPY-induced NO and IL-1β production in microglia (Ferreira et al., [@B23]). However, further studies are required to elucidate the exact mechanism of action and the signaling pathway utilized by NPY receptors to transducer it beneficial effects.

Taken together our studies suggest that the ADAPT-232 and its active constituent salidroside act on NPY expression *via* a mechanism dependent on the upregulation of HSF1 expression, which is upstream of Hsp72 expression, which is upstream of Hsp72 release (Figure [7](#F7){ref-type="fig"}). Our hypothetical model suggest that the release of Hsp72 take place *via* a mechanism dependent on the upregulation of NPY, which is upstream of Hsp72 and all other mediators of stress response involved in effects of ADAPT-232 (Figure [7](#F7){ref-type="fig"}). ADAPT-232 stimulates secretion of NPY which is known to play an important role in regulation of HPA axis and energy homeostasis and secretion of Hsp72, playing an important role in cytoprotection and innate immunity. Hsp72 in turn inhibits FoxO transcription factor, playing an important role in adaptation to stress and longevity (Lam et al., [@B36]; Senf et al., [@B65]). These pathways contribute the anti-fatigue effect of ADAPT, increase attention and the improvement in cognitive function. The activation of NPY by ADAPT-232 initiates Hsp72 expression in human neuroglia cells, which are known to maintain homeostasis of neuronal cells. Stimulation and release of these stress hormones (NPY and Hsp72) into the blood circulating system apparently is an innate defense response to mild stressors (adaptogens), which increases tolerance and adaptation to stress. This gives rise to adaptive and stress--protective effects *via* various components of central nervous, sympathetic, endocrine, immune, cardiovascular, and gastrointestinal systems. Both NPY and Hsp72 play important roles in stress, regulation of aging, and pathogenesis of age-related diseases (Kmiec, [@B33]; Calderwood et al., [@B14]; Rasmusson et al., [@B59]). Taken together, the data presented in this study suggests that adaptogenic activity of ADAPT-232, such as increased mental performance, attention, endurance, tolerance to stress, and beneficial effects on age-related disorders are associated with activation of NPY and Hsp72 gene expression in neuroglia cells and the release of NPY and Hsp72 into the systemic blood circulation.

![**Schematics representation of the hypothetical working model for the effect of ADAPT-232 on neuroglia cells**. ADAPT-232 (green star) and its active constituent salidroside activated the synthesis and release of NPY and Hsp72 *via* a HSF1-dependent mechanism, including the trimerization and nuclear translocation of HSF1 (blue circles). Hsp72 functions intracellularly to enhance anti-apoptotic mechanisms, protect proteins against mitochondria generated oxygen-containing radicals, including nitric oxide (red star) and superoxide anion (purple star). The released Hsp72 acts as an endogenous danger signal and plays an important role in immune stimulation. While released NPY plays a crucial role in the HPA axis and maintains energy balance, both NPY and Hsp72 are directly involved in cellular adaptation to stress, increased survival, enhanced longevity, and an improvement in cognitive function.](fnins-06-00006-g007){#F7}
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